N-(4-fluorophenyl)-2-(4-formylphenoxy)acetamide | 428474-35-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-fluorophenyl)-2-(4-formylphenoxy)acetamide
• CAS: 428474-35-5
• 化学式: C₁₅H₁₂FNO₃
• mdl: MFCD02629647
• 分子量: 273.264
• InChiKey: MECMKAQXWOLNNW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  巴比妥酸 、 N-(4-fluorophenyl)-2-(4-formylphenoxy)acetamide 在 对甲苯磺酸 作用下， 以 甲醇 、 水 为溶剂， 以87%的产率得到N-(4-fluorophenyl)-2-(4-((2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene)methyl)phenoxy)acetamide
  参考文献：
  名称：

  作为强效脲酶抑制剂的新型（硫代）巴比妥酸-苯氧基-N-苯基乙酰胺衍生物：合成、体外脲酶抑制和计算机评估

  摘要：

  合成了一系列新的（硫代）巴比妥酸-苯氧基-N-苯基乙酰胺衍生物 7a-1，并针对幽门螺杆菌脲酶进行了评估。后一种测定表明，所有合成的化合物 7a-l (IC 50 = 0.69 ± 0.33–2.47 ± 0.23 μM) 比两种使用的标准抑制剂硫脲 (IC 50 = 23 ± 0.73 μM) 和羟基脲 (IC 50 = 100 ± 1.7 μM）。对合成化合物的对接研究表明，这些化合物也适合脲酶活性位点。此外，对最有效化合物 7d 的分子动力学研究表明，该化合物与活性位点瓣残基 Cys592 和 His593 产生了重要的相互作用。此外，计算机药代动力学研究预测所有合成的化合物都是类似药物的。

  DOI：

  10.1007/s11224-020-01617-6
• 作为产物：
  描述：

  4-氟苯胺 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 生成 N-(4-fluorophenyl)-2-(4-formylphenoxy)acetamide
  参考文献：
  名称：

  作为强效脲酶抑制剂的新型（硫代）巴比妥酸-苯氧基-N-苯基乙酰胺衍生物：合成、体外脲酶抑制和计算机评估

  摘要：

  合成了一系列新的（硫代）巴比妥酸-苯氧基-N-苯基乙酰胺衍生物 7a-1，并针对幽门螺杆菌脲酶进行了评估。后一种测定表明，所有合成的化合物 7a-l (IC 50 = 0.69 ± 0.33–2.47 ± 0.23 μM) 比两种使用的标准抑制剂硫脲 (IC 50 = 23 ± 0.73 μM) 和羟基脲 (IC 50 = 100 ± 1.7 μM）。对合成化合物的对接研究表明，这些化合物也适合脲酶活性位点。此外，对最有效化合物 7d 的分子动力学研究表明，该化合物与活性位点瓣残基 Cys592 和 His593 产生了重要的相互作用。此外，计算机药代动力学研究预测所有合成的化合物都是类似药物的。

  DOI：

  10.1007/s11224-020-01617-6

文献信息

• Bi-functional complexes and methods for making and using such complexes
  申请人：Gouliaev Alex Haahr

  公开号：US11225655B2

  公开（公告）日：2022-01-18

  The present invention is directed to a method for the synthesis of a bi-functional complex comprising a molecule part and an identifier oligonucleotide part identifying the molecule part. A part of the synthesis method according to the present invention is preferably conducted in one or more organic solvents when a nascent bi-functional complex comprising an optionally protected tag or oligonucleotide identifier is linked to a solid support, and another part of the synthesis method is preferably conducted under conditions suitable for enzymatic addition of an oligonucleotide tag to a nascent bi-functional complex in solution.

  本发明涉及一种合成双功能复合物的方法，该复合物包括分子部分和识别分子部分的识别寡核苷酸部分。根据本发明的合成方法的一部分优选在一种或多种有机溶剂中进行，此时包含可选保护标签或寡核苷酸标识符的新生双功能复合物与固体支持物相连接，合成方法的另一部分优选在适合于将寡核苷酸标签酶加到溶液中的新生双功能复合物的条件下进行。
• Synthesis of novel 1-alkyl-8-substituted-3-(3-methoxypropyl) xanthines as putative A2B receptor antagonists
  作者：María Isabel Nieto、María Carmen Balo、José Brea、Olga Caamaño、María Isabel Cadavid、Franco Fernández、Xerardo García Mera、Carmen López、José Enrique Rodríguez-Borges

  DOI：10.1016/j.bmc.2009.03.029

  日期：2009.5

  In order to identify a high-affinity, selective antagonist for the A(2B) subtype adenosine receptor, more than 40 1,8-disubstituted-3-(3-methoxypropyl) xanthines were prepared and evaluated for their binding affinity at recombinant human adenosine receptors, mainly of the A(2A) and A(2B) subtypes. Some of the 1-ethyl-3-(3-methoxypropyl)-8-aryl substituted derivatives 15(a-m) showed moderate-to-high affinity at human A(2B) receptors, with compound 15d showing A(2B) selectivity over the other A receptors assayed (A(1), A(2A), A(3)) of 34-fold or over. (C) 2009 Elsevier Ltd. All rights reserved.
• Synthesis and Biological Evaluation of Novel 5-Benzylidenethiazolidine-2,4-dione Derivatives for the Treatment of Inflammatory Diseases
  作者：Liang Ma、Caifeng Xie、Yinghua Ma、Juan Liu、Mingli Xiang、Xia Ye、Hao Zheng、Zhizhi Chen、Qinyuan Xu、Tao Chen、Jinying Chen、Jincheng Yang、Neng Qiu、Guangcheng Wang、Xiaolin Liang、Aihua Peng、Shengyong Yang、Yuquan Wei、Lijuan Chen

  DOI：10.1021/jm1011534

  日期：2011.4.14

  Twenty-two compounds based on thiazolidine-2,4-dione moiety were synthesized and evaluated for the inhibitory potency on the production of nitric oxide (NO), inducible nitric oxide synthase (iNOS) activity, and the generation of prostaglandin E-2 (PEG(2)). (Z)-N-(3-Chlorophenyl)-2-(4-((2,4-dioxothiazolidin-5-ylidene) methyl) phenoxy) acetamide (3I), superior to the commercial anti-inflammatory drug indomethacin, significantly inhibited iNOS activity (IC50 = 8.66 mu M), iNOS-mediated NO, and cyclooxnenase (COX)-2-derived PGE(2) production (IC50 = 4.16 and 23.55 mu M, respectively) on lipopolysaccharide (LPS)-induced. RAW 264.7 cells. Docking study revealed that 3I was perfectly docking into the active site of murine iNOS and suppressed the expression of iNOS protein as evidenced by Western blot analysis. At the dose of 50 mg/kg, oral administration of 3I possessed protective properties in both carrageenan-induced paw edema and adjuvant-induced arthritis rat models.
• Synthesis and biological activity of novel barbituric and thiobarbituric acid derivatives against non-alcoholic fatty liver disease
  作者：Liang Ma、Shilin Li、Hao Zheng、Jinying Chen、Lin Lin、Xia Ye、Zhizhi Chen、Qinyuan Xu、Tao Chen、Jincheng Yang、Neng Qiu、Guangcheng Wang、Aihua Peng、Yi Ding、Yuquan Wei、Lijuan Chen

  DOI：10.1016/j.ejmech.2011.02.033

  日期：2011.6

  Forty-four barbituric acid or thiobarbituric acid derivatives were synthesized and evaluated for their effects on adipogenesis of 3T3-L1 adipocytes by measuring the expression of adiponectin in vitro. Four compounds (3a, 30, 3s, 4t) were found to increase the expression of adiponectin and lower the leptin level in 31341 adipocytes at respective concentration of 10 mu M. Among them, 3s showed the most efficacious. Oral administration of 3s effectively reduced body weight, liver weight, and visceral fat and regulated serum levels of biochemical markers in the high-fat/diet-induced Wistar rats. Histopathological evaluation of liver sections by Oil Red O and H&E staining confirmed 3s as a potent, orally active molecule for reducing fat deposition against non-alcoholic fatty liver disease. (C) 2011 Elsevier Masson SAS. All rights reserved.
• Computer-aided identification, synthesis, and biological evaluation of novel inhibitors for botulinum neurotoxin serotype A
  作者：Yu-Han Gary Teng、William T. Berger、Natasha M. Nesbitt、Kunal Kumar、Trent E. Balius、Robert C. Rizzo、Peter J. Tonge、Iwao Ojima、Subramanyam Swaminathan

  DOI：10.1016/j.bmc.2015.07.040

  日期：2015.9

  Botulinum neurotoxins (BoNTs) are among the most potent biological toxin known to humans, and are classified as Category A bioterrorism agents by the Centers for Disease Control and prevention (CDC). There are seven known BoNT serotypes (A-G) which have been thus far identified in literature. BoNTs have been shown to block neurotransmitter release by cleaving proteins of the soluble NSF attachment protein receptor (SNARE) complex. Disruption of the SNARE complex precludes motor neuron failure which ultimately results in flaccid paralysis in humans and animals. Currently, there are no effective therapeutic treatments against the neurotoxin light chain (LC) after translocation into the cytosols of motor neurons. In this work, high-throughput in silico screening was employed to screen a library of commercially available compounds from ZINC database against BoNT/A-LC. Among the hit compounds from the in silico screening, two lead compounds were identified and found to have potent inhibitory activity against BoNT/A-LC in vitro, as well as in Neuro-2a cells. A few analogs of the lead compounds were synthesized and their potency examined. One of these analogs showed an enhanced activity than the lead compounds. (C) 2015 Elsevier Ltd. All rights reserved.